4D Molecular Therapeutics
FDMT
80 hedge funds and large institutions have $395M invested in 4D Molecular Therapeutics in 2022 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 32 increasing their positions, 27 reducing their positions, and 7 closing their positions.
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
19% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 27
4.49% more ownership
Funds ownership: 76.86% → 81.35% (+4.5%)
4% more funds holding
Funds holding: 77 → 80 (+3)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
27% less capital invested
Capital invested by funds: $541M → $395M (-$146M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$10.3M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$8.61M |
| 3 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$3.86M |
| 4 |
State Street
Boston,
Massachusetts
|
+$3.61M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PWM
Perigon Wealth Management
San Francisco,
California
|
-$3.29M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$2.9M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.19M |
| 4 |
Russell Investments Group
London,
United Kingdom
|
-$883K |
| 5 |
Two Sigma Investments
New York
|
-$866K |
FDMT Hedge Fund Activity: Q1 2022 in Review
80 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in 4D Molecular Therapeutics (FDMT) for Q1 2022, worth a combined $395M — down 27% from $541M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new FDMT positions and 7 closed out — a net gain of 3 holders — while 32 added to existing stakes and 27 trimmed.
The largest buyer was BVF Inc, adding an estimated $10.3M. The largest seller was Perigon Wealth Management, cutting an estimated $3.29M.
- 80 institutional investors held 4D Molecular Therapeutics (FDMT) as of Q1 2022, up from 77 in Q4 2021.
- Funds reported $395M of 4D Molecular Therapeutics stock for Q1 2022, down 27% quarter-over-quarter.
- 10 funds opened new 4D Molecular Therapeutics positions in Q1 2022 and 7 closed out, a net change of +3 holders.
- The largest 4D Molecular Therapeutics buyer in Q1 2022 was BVF Inc, an estimated $10.3M added.
- The largest 4D Molecular Therapeutics seller in Q1 2022 was Perigon Wealth Management, an estimated $3.29M sold.
Based on aggregated 13F filings for Q1 2022.